A Phase 3 interventional study of Nepafenac 1mg/ml eye drops, suspension and Ketorolac Trometamol 5 mg/ml eye drops, solution in Cataracts, sponsored by Alcon Research. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-18.
Sponsored by Alcon Research · Phase 3, Interventional, and Treatment
To evaluate the safety and efficacy of Nepafenac 1 mg/ml Eye Drops, Suspension, compared to Placebo and Ketorolac Trometamol 5 mg/ml Eye Drops, Solution for the prevention and treatment of ocular inflammation and ocular pain after cataract extraction with IOL implantation
1,701 studies on the registry are indexed under Cataract; 230 are open to participants now.
This study's enrollment of 227 is above the median of 80 across 1,155 interventional studies indexed under Cataract.
Browse Cataract studies →Alcon Research is the lead sponsor of 608 studies on the registry; 9 are open to participants now.
Of its 109 completed or terminated interventional studies of FDA-regulated products, 99 (91%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
One drop in the study eye 3 times daily for 23 days
Drug: Nepafenac 1mg/ml eye drops, suspension
One drop in the study eye 3 times daily for 23 days
Drug: Ketorolac Trometamol 5 mg/ml eye drops, solution
One drop in the study eye 3 times daily for 23 days
Other: Nepafenac vehicle eye drops
One drop in the study eye 3 times daily for 23 days
One drop in the study eye 3 times daily for 23 days
One drop in the study eye 3 times daily for 23 days
Percentage of Patients with Day 14 Cure
Cure is defined as aqueous cells score = 0 and aqueous cells score = 0 at Day 14.
Time frame: Day 14
This study is completed, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Alcon Research